China's National Medical Products Administration has approved a significant number of domestically developed innovative drugs this year, highlighting a robust biotech sector. This trend signifies a growing strength in China's pharmaceutical industry.

Home-grown innovative drugs make up most of the medicines China’s drug regulator has approved for sale so far this year, underscoring the country’s biotech boom. Of the 19 innovative drugs cleared by the National Medical Products Administration (NMPA), 15 came from domestic companies, according to the regulator’s website as of May 21. These include sonrotoclax, developed by global biopharmaceutical firm BeOne, for treating certain adult blood cancers. The regulator overhauled its approval...